

## DAFTAR PUSTAKA

1. World Health Organization. Cardiovascular disease (CVDs) [Internet]. 2017 [cited 2019 Nov 28]. Available from: [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)).
2. Penyakit jantung penyebab kematian tertinggi, kemenkes ingatkan cerdas [Internet]. 2017 [cited 2019 Nov 28]. Available from: <https://www.depkes.go.id/article/print/17073100005/penyakit-jantung-penyebab-kematian-tertinggi-kemenkes-ingatkan-cerdik-.html>
3. Riskesdas K. Hasil Utama Riset Kesehatan Dasar (RISKESDAS). *J Phys A Math Theor* [Internet]. 2018;44(8):1–200. Available from: [http://www.kesmas.kemkes.go.id/assets/upload/dir\\_519d41d8cd98f00/files/Hasil-riskesdas-2018\\_1274.pdf](http://www.kesmas.kemkes.go.id/assets/upload/dir_519d41d8cd98f00/files/Hasil-riskesdas-2018_1274.pdf)
4. Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J. Larry Jameson JL. Harrison. *Principios de Medicina Interna*, 20 Ed. | McGraw-Hill Medical. Harrison. 2018.
5. Kemenkes RI. Situasi kesehatan jantung. Pus data dan Inf Kementeri Kesehatan RI [Internet]. 2014;3. Available from: <http://www.depkes.go.id/download.php?file=download/pusdatin/infodatin/infodatin-jantung.pdf>
6. Aman A, Soewondo P, Soelistijo S, Arsana P, Wismandari, Zufry H, et al. *Pedoman Pengelolaan Dislipidemia Di Indonesia*. PB Perkeni; 2019. 5 p.
7. Erwinanto, Santoso A, Purtanto J, Tedjasukmana P, Suryawan R, Rifqi S, et al. *Pedoman Tatalaksana Dislipidemia*. PP PERKI; 2013. 2 p.
8. Kopin L, Lowenstein CJ. Dyslipidemia. *Ann Intern Med*. 2017;167(11):275–9.
9. Hendrani AD. Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. *World J Cardiol*. 2016;8(2):201.
10. Arsana P, Rosandi R, Manaf A, Budhiarta A, Permana H, Sucipta K, et al. *Panduan pengelolaan dislipidemia di Indonesia*. Pb Perkeni. 2015;4.
11. Rubba P, Marotta G, Gentile M. Efficacy and safety of rosuvastatin in the management of dyslipidemia. *Vasc Health Risk Manag*. 2009;5:343–52.
12. Bajaj T, Giwa AO. Rosuvastatin [Internet]. *StatPearls*. 2019. Available from:

<https://www.ncbi.nlm.nih.gov/books/NBK539883/#article-31521.s10>

13. Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: A review of the pharmacology and clinical effectiveness in cardiovascular disease. *Clin Med Insights Cardiol.* 2012;6:17–33.
14. Karimi A, Majlesi M, Rafieian-Kopaei M. Herbal versus synthetic drugs; beliefs and facts. *J nephropharmacology* [Internet]. 2015;4(1):27–30. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28197471> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5297475>
15. Sarker M, Mahmud ZA, Saha SK, Tithi NS, Ali MS, Bachar SC. Antihyperlipidemic activity of flowers of punica granatum in poloxamer-407 induced hyperlipidemic mice model. *Pharmacogn J.* 2012;4(27):66–70.
16. Barakat L, Jayyousi A, Bener A, Zuby B, Zirie M. Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients. *ISRN Pharmacol.* 2013;2013:1–7.
17. Shuhaili MFRMA, Samsudin IN, Stanslas J, Hasan S, Thambiah SC. Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians. *int j endocrinol metab.* 2017;15(2):1–12.
18. Sargowo D. Patogenesis Aterosklerosis. UB Press; 2015. 2–14 p.
19. Lintong P. Perkembangan Konsep Patogenesis Aterosklerosis. *J Biomedik.* 2013;1(1).
20. Handono K, Kalim H, Nurdiana, Susianti H, Wahono CS, Hasanah D, et al. Vitamin D dan Autoimunitas. UB Press; 2018. 1–21 p.
21. Sudoyo aru W. Buku ajar ilmu penyakit dalam. 5th ed. jakarta: interna publishing; 2009.
22. Zulviana E, Rahman N, Supriadi. Pengaruh pemberian ekstrak buah kelor (*Moringa oleifera*) Terhadap Penurunan Kadar Kolesterol Pada Darah Hewan Mencit (*Mus Musculus*) Effect. 2017;6(1):15–20.
23. Tebben PJ, Singh RJ, Kumar R. Vitamin D-mediated hypercalcemia: Mechanisms, diagnosis, and treatment. *Endocr Rev.* 2016;37(5):521–47.
24. Kurniati NF, Nurfatwa M, Artarini AA. Aktivitas Makrofag Meningkat Pada Aorta Tikus Hiperkolesterolemia. *Maj Kedokt Bandung.* 2018;50(1):13–20.
25. Calza L. Long-term use of rosuvastatin: A critical risk benefit appraisal and

- comparison with other antihyperlipidemics. *Drug Healthc Patient Saf.* 2009;1(1):25–33.
26. Jurenka J. Therapeutic applications of pomegranate (*Punica granatum* L.): A review. *Altern Med Rev.* 2008;13(2):128–44.
  27. Liu C, Sun J, Lu Y, Bo Y. Effects of anthocyanin on serum lipids in dyslipidemia patients: A systematic review and meta-analysis. *PLoS One.* 2016;11(9):1–11.
  28. Zhang L, Fu Q, Zhang Y. Composition of anthocyanins in pomegranate flowers and their antioxidant activity. *Food Chem* [Internet]. 2011;127(4):1444–9. Available from: <http://dx.doi.org/10.1016/j.foodchem.2011.01.077>
  29. Reis JF, Monteiro VVS, Souza Gomes R, Carmo MM, Costa GV, Ribera PC, et al. Action mechanism and cardiovascular effect of anthocyanins: A systematic review of animal and human studies. *J Transl Med.* 2016;14(1):1–16.
  30. BenSaad LA, Kim KH, Quah CC, Kim WR, Shahimi M. Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A&B isolated from *Punica granatum*. *BMC Complement Altern Med* [Internet]. 2017;17(1):1–10. Available from: <http://dx.doi.org/10.1186/s12906-017-1555-0>
  31. Jia Y, Kim S, Kim J, Kim B, Wu C, Lee JH, et al. Ursolic acid improves lipid and glucose metabolism in high-fat-fed C57BL/6J mice by activating peroxisome proliferator-activated receptor alpha and hepatic autophagy. *Mol Nutr Food Res.* 2015;59(2):344–54.
  32. Meeran MFN, Goyal SN, Suchal K, Sharma C, Patil CR, Ojha SK. Pharmacological properties, molecular mechanisms, and pharmaceutical development of asiatic acid: A pentacyclic triterpenoid of therapeutic promise. *Front Pharmacol.* 2018;9(SEP).
  33. Xu G, Sun W, Guo X, Wu L, Hou Y, Ma X, et al. Asiatic acid promotes liver fatty acid metabolism in diabetic models. *Int J Clin Exp Med.* 2018;11(11):11837–45.
  34. Liu J, Sun H, Wang X, Mu D, Liao H, Zhang L. Effects of Oleanolic Acid and Maslinic Acid on Hyperlipidemia. *drug Dev Res.* 2007;68:261–6.
  35. Yap WH, Ooi BK, Ahmed N, Lim YM. Maslinic acid modulates secreted phospholipase A2-IIA (sPLA2-IIA)-mediated inflammatory effects in macrophage foam cells formation. *J Biosci.* 2018;43(2):277–85.

36. Akoh CC. Food Lipids Chemistry, Nutrition, and Biotechnology. 4th ed. CRC Press Web; 2017. 3–4 p.
37. Rodwell WV, Bender AD, Botham M Kathleen, Kennelly J Peter, Weil AP. Illustrated Biochemistry. 30 th. Mc Graw Hill Education; 2013. 211 p.
38. Jim EL. Metabolisme Lipoprotein. J Biomedik. 2014;5(3).
39. Wahjuni S. metabolisme biokimia. Vol. 53, Journal of Chemical Information and Modeling. 2013. 1689–1699 p.
40. Schochet L, Jialal I. Biochemistry, Lipoprotein Metabolism [Internet]. StatPearls. 2020 [cited 2020 Aug 19]. p. 1–5. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK553193/>
41. Feingold K, Grunfeld C. Introduction to Lipids and Lipoproteins [Internet]. NCBI Bookshelf; 2018 [cited 2020 Aug 20]. p. 1–25. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK305896/>
42. Adam john M. Buku Ajar Ilmu Pengetahuan Dalam Jilid III. In: Sudoyo AW, Setiyohadi B, Alwi I, K simadibrata M, Setiati S, editors. IV. jakarta: interna publishing; 2010. p. 1984–92.
43. Venugopal KS, Anoruo M, Jialal I. Biochemistry, Low Density Lipoprotein [Internet]. StatPearls. 2020 [cited 2020 Aug 21]. p. 1–6. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK500010/>
44. Zhang R, Naughton DP. Vitamin D in health and disease: Current perspectives. Nutr J [Internet]. 2010;9(1):65. Available from: <http://www.nutritionj.com/content/9/1/65>
45. Lutsey PL, Michos ED. Vitamin D, calcium, and atherosclerotic risk: Evidence from serum levels and supplementation studies. Curr Atheroscler Rep. 2013;15(1):1–13.
46. Ismawati, Oenzil F, Yanwirasti, Yerizel E. Changes in expression of proteasome in rats at different stages of atherosclerosis. Anat Cell Biol. 2016;49(2):99–106.
47. Ismawati I, Oenzil F, Yanwirasti Y, Yerizel E. Analisis Konsentrasi Low Density Lipoprotein Teroksidasi Serum pada Tahapan Aterosklerosis. J Kedokt Brawijaya. 2017;29(4):348–52.
48. Bajaj T, Giwa AO. Rosuvastatin [Internet]. StatPearls. 2020 [cited 2020 Sep 1]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539883/%0A>

49. Kumar V, Abbas AK, Aster JC. Robbin Basic Pathology. Robbins Basic Pathology. 2012.
50. Andriani V. Karakterisasi Anatomi Delima (*Punica granatum* L.). *Stigma J Sci.* 2016;9(2):6–7.
51. Direktorat Obat Asli Indonesia. Acuan Sediaan Herbal. 2011;6(9):1689–99.
52. Rukmana HR. Tabulampot : Delima. yogyakarta: kanisius; 2003. 11–12 p.
53. Pakyürek M, Al-Jabbari KH, Yaviç A. Identification of Morphological and Pomological Characteristics of Iraq Pomegranate (*Punica granatum* L.) Variety Salakhani and Comparing with Variety Zivzik. *Int J Second Metab.* 2019;6(3):270–82.
54. Houtt MF. classification for Kingdom Plantae Down to Species *Punica granatum* L. [Internet]. [cited 2020 Oct 4]. Available from: <https://plants.usda.gov/java/ClassificationServlet?source=profile&symbol=CIZE2&display=31>
55. Dalimartha. Atlas Tumbuhan Obat Indonesia Jilid Ketiga. jakarta: Puspa Swara;
56. Wetzstein HY, Ravid N, Wilkins E, Martinelli AP. A morphological and Histological characterization of bisexual and male flower types in pomegranate. *J Am Soc Hortic Sci.* 2011;136(2):83–92.
57. Sadeghipour A, Eidi M, Ilchizadeh KA, Ghahramani R, Shahabzadeh S, Anissian A. Lipid lowering effect of *punica granatum* L. Peel in high lipid diet fed male rats. *Evidence-based Complement Altern Med.* 2014;2014.
58. Elfalleh W. Total phenolic contents and antioxidant activities of pomegranate peel, seed, leaf and flower. *J Med Plants Res.* 2012;6(32).
59. Qin Y, Xia M, Ma J, Hao YT, Liu J, Mou HY, et al. Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. *Am J Clin Nutr.* 2009;90(3):485–92.
60. Wallace TC, Slavin M, Frankenfeld CL. Systematic review of anthocyanins and markers of cardiovascular disease. *Nutrients.* 2016;8(1):1–13.
61. Hajimahmoodi M, Moghaddam G, Ranjbar AM, Khazani H, Sadeghi N, Oveisi MR, et al. Total Phenolic, Flavonoids, Tannin Content and Antioxidant Power of Some Iranian Pomegranate Flower Cultivars (&lt;i>Punica granatum&lt;/i> L.). *Am J Plant Sci.*

2013;04(09):1815–20.

62. Stefanou V, Papatheodorou S, Vougiouklaki D, Antonopoulos D, Lougovois V, Tsaknis I, et al. Medicinal Properties of Antioxidant Pomegranate in Cardiovascular Health. *Adv Res Publ Int J Prev Cardiol* [Internet]. 2020;2020(1):10–9. Available from: <https://orcid.org/0000-0003-2856-4206>
63. Zeka K, Ruparelia K, Arroo R, Budriesi R, Micucci M. Flavonoids and Their Metabolites: Prevention in Cardiovascular Diseases and Diabetes. *Diseases*. 2017;5(3):19.
64. BenSaad LA, Kim KH, Quah CC, Kim WR, Shahimi M. Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A&B isolated from *Punica granatum*. *BMC Complement Altern Med* [Internet]. 2017;17(1):1–10. Available from: <http://dx.doi.org/10.1186/s12906-017-1555-0>
65. Al-Muammar MN, Khan F. Obesity: The preventive role of the pomegranate (*Punica granatum*). *Nutrition* [Internet]. 2012;28(6):595–604. Available from: <http://dx.doi.org/10.1016/j.nut.2011.11.013>
66. Hsu CL, Yen GC. Effect of gallic acid on high fat diet-induced dyslipidaemia, hepatosteatosis and oxidative stress in rats. *Br J Nutr*. 2007;98(4):727–35.
67. Pang J, Xu Q, Xu X, Yin H, Xu R, Guo S, et al. Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. *Peptides* [Internet]. 2010;31(4):630–8. Available from: <http://dx.doi.org/10.1016/j.peptides.2009.11.007>
68. Departemen Kesehatan RI. *Pedoman Pengujian dan Pengembangan Fitofarmaka : Penapisan Farmakologi, Pengujian Fitokimia dan Pengujian Klinik*. Jakarta: Yayasan Pengembangan Obat Bahan Alam Phyto Medica.; 1993.
69. Stevani H. *Praktikum Farmakologi*. Kementerian Kesehatan Republik Indonesia. 2016. 171 p.
70. Silsia D, Efendi Z, Timotius F. Karakterisasi Karboksimetil Selulosa (CMC) Dari Pelepah Kelapa Sawit. *J Agroindustri*. 2018;8(1):53–61.
71. Artiss J, Zak D. *Measurement of cholesterol concentration*. aacc press; 1997. 99–114 p.
72. Hanafiah K. *Rancangan Percobaan Aplikatif : Aplikasi Kondisional Bidang Pertanian, Peternakan, Perikanan, Industri, dan Hayati*. Raja Grafindo Persada; 2005.

73. Tim Riset Kesehatan Dasar Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan. Pedoman Pengambilan, Penyimpanan, Pengemasan dan Pengiriman Spesimen Darah. 2007;
74. Bachorik PS, Ross JW. National cholesterol education program recommendations for measurement of low-density lipoprotein cholesterol: Executive summary. Vol. 41, Clinical Chemistry. 1995. p. 1414–20.
75. Bachorik P. Measurement of Low-Density-Lipoprotein Cholesterol. In: Rifai N, Warnick GR, Dominiczak MH, eds. AACC Press. 2000;12:245–63.

